<DOC>
	<DOCNO>NCT02319460</DOCNO>
	<brief_summary>This observational cohort study design obtain product safety information routine clinical setting within large , diverse , community-based population . In set acute major bleed patient treat Vitamin K antagonist reversal , risk thromboembolic event ( TEE ) patient treat Kcentra® patient treat plasma assess .</brief_summary>
	<brief_title>An Observational Cohort Study Investigate Risk Thromboembolic Events Patients Receiving Kcentra® Plasma Reverse Vitamin K Antagonist ( VKA ) Therapy Setting Acute Major Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Protein S</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Aged 18 year old admission VKAassociated major bleed A minimum 365 day continuous health plan enrollment index hospitalization involve acute VKA reversal treatment A minimum 365 day continuous pharmacy benefit index hospitalization involve acute VKA reversal treatment Patients exclude primary analysis : Require urgent reversal VKA therapy set bleed due major trauma ( eg , motor vehicle accident ) Requiring urgent reversal VKA therapy surgical procedure unrelated major bleeding ( eg , appendicitis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Reversal Vitamin K Antagonist Therapy Setting Acute Major Bleeding</keyword>
	<keyword>Warfarin Reversal</keyword>
</DOC>